Diagnosis and prognosis in childhood neuroblastoma.
| Inventor | Institute |
|---|---|
| Gerard Evan | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 151136 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Genetics |
| Application: | ChIP ; IHC ; IF ; IP ; WB ; EMSA |
| Target: | nMyc |
| Reactivity: | Human |
| Clone: | NMYC-1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | Diagnosis and prognosis in childhood neuroblastoma. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG2b |
| Molecular weight: | 27 kDa |
| Immunogen: | Human N myc peptide sequence SPYVESEDAPPQKC conjugated to KLH. |
| Immunogen Uniprot ID: | P11487 |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | Diagnosis and prognosis in childhood neuroblastoma. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Tasseva et al. 2011. J Biol Chem. 286(2):1061-73. PMID: 21068393. N-Myc and SP regulate phosphatidylserine synthase-1 expression in brain and glial cells. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151023 | Anti-IL12 [1-1D5] |
Key Info
Anti-IL12 [1-1D5]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.